Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
Click to take the #AdvantageHers chronic inflammatory diseases questionnaire, developed in partnership with @CaroWozniacki to help evaluate your role in the development of a unique treatment game plan: https://t.co/LZh4PmO2Sz
— UCB News (@ucb_news) 16.04.2021 -
UCB is proud to showcase new research at the 73rd American Academy of Neurology Annual Meeting starting tomorrow, demonstrating our broad neurology portfolio and future innovations. Join us here to learn more #AANAM
— UCB News (@ucb_news) 16.04.2021 -
Register for the #Immunologysummit2021 TODAY to discover the Summit agenda. Be sure to choose your topic of interest upon registration!
— UCB News (@ucb_news) 16.04.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
